Intervention not reported
Serious adverse events during the trial period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in serious adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
It is very uncertain whether the intervention changes serious adverse events during the trial period (very low certainty).
1 finding from 1 review
Adverse events (machine tolerability outcomes) · adults with a diagnosis of sleep apnoea
1 finding from 1 review
Adverse events (machine tolerability outcomes) · adults with a diagnosis of OSA
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in toxicity (adverse events probably due to drug) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract showed no clear difference in toxicity (adverse events probably due to drug) compared with antifungal drugs not absorbed from GI tract; GRADE not reported.
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Adverse events: minor gastrointestinal symptoms · healthy people and healthy male physicians
Vitamin A leads to higher adverse events: minor gastrointestinal symptoms compared with placebo (high certainty).
1 finding from 1 review
Major adverse cardiac and cerebrovascular events · people with or without existing CVD, men and women
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes major adverse cardiac and cerebrovascular events compared with lower PUFA (very low certainty).
1 finding from 1 review
Adverse events (acute complication after surgery)
It is very uncertain whether suprapubic catheterisation changes adverse events (acute complication after surgery) compared with intermittent self‐catheterisation (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events associated with RAT — not measured · Workers in positions with safety‐sensitive functions, other than commercial drivers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events related to taking of blood samples · children aged 6 to 12 years
1 finding from 1 review
Non‐serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ shock · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ shock compared with placebo compared (high certainty).
1 finding from 1 review
Malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy (range 30 to 36 months compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
Intervention not reported
Discontinuation of study drug due to adverse events · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention probably leads to lower discontinuation of study drug due to adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Discontinuation of study drug due to adverse events · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
It is very uncertain whether an extended NVP plus ZDV regimen administered to infants for 14 weeks changes infants with Probably Related Severe Adverse Events compared with sdNVP plus ZDV (1 week) (very low certainty).
1 finding from 1 review